MTOR and prostate cancer: Fisetin has been shown to be a dual inhibitor of PI3K/AKT and mTOR in prostate cancer cells and in human NSCLC cells, as well as an inducer of autophagy in pancreatic cancer cells via ER stress- and mitochondrial stress-dependent pathways [129,130].